Previous Article | Next Article ![]()
Infection and Immunity, January 2001, p. 538-542, Vol. 69, No. 1
Département de Biologie
Moléculaire et Structurale, BBSI, UMR 5092 CNRS, CEA
Grenoble, 38054 Grenoble Cedex 09, France
Received 1 June 2000/Returned for modification 18 August
2000/Accepted 4 October 2000
Twelve Pseudomonas aeruginosa cystic fibrosis isolates
that are not able to exert a type III secretion system (TTSS)-dependent cytotoxicity towards phagocytes have been further studied. The strains,
although possessing TTSS genes and exsA, which encodes a
positive regulator of the TTSS regulon, showed no transcriptional activation of the exsCBA regulatory operon. The expression
of exsA in trans restored the in vitro secretion of TTSS
proteins and ex vivo cytotoxicity.
Pseudomonas aeruginosa is
an opportunistic pathogen which affects numerous compromised human
hosts, most notably cystic fibrosis (CF) patients. Chronic respiratory
infections and inflammatory responses cause progressive pulmonary
tissue destruction, which is often fatal for CF patients
(5). The pulmonary damage is attributed on the one hand to
the uncontrolled release of toxic mediators from an excessive number of
necrotic polymorphonuclear neutrophils (PMNs) at the site of infection
(17, 19) and on the other to the synthesis and
accumulation of bacterial products (4). A number of
virulence proteins produced by P. aeruginosa that contribute
to its pathogenesis have been characterized (11).
A novel virulence mechanism has been recently identified as the type
III secretion system (TTSS), which is able to provoke eukaryotic cell
intoxication (15, 27). TTSSs are conserved in many
gram-negative pathogens and encode on the order of 20 proteins
assembled into a complex to secrete and translocate effectors into
eukaryotic cell (14). To date, four TTSS-secreted
effectors have been identified in P. aeruginosa isolates:
ExoS, ExoT, ExoU, and ExoY. ExoS and ExoT are closely related
ADP-ribosyltransferases (9, 18, 20-22), ExoY is an
adenylate cyclase (29), and ExoU (PepA) is a cytotoxin
with unidentified activity (7, 12, 23). We have recently
reported that a CF clinical isolate, CHA, is able to induce rapid
oncosis of PMNs and macrophages. The cytotoxicity is TTSS dependent but
is independent of the toxin ExoU (2, 3). A survey of 29 P. aeruginosa CF isolates showed that 6 strains were able to
secrete type III proteins in vitro and to provoke ExoU-independent
oncosis of phagocyte cells. However most of the strains found to be
noncytotoxic in an ex vivo infection model possess the type III
effector genes and the exsA gene, which encodes the
transcriptional activator of the TTSS regulon (3, 13).
We showed in this study that expression of the activator of the TTSS
regulon, ExsA, in trans was sufficient to activate in vitro secretion
and ex vivo cytotoxicity toward phagocytes in 9 out of 12 noncytotoxic
isolates tested.
The relevant properties of all strains and plasmids used in this study
are summarized in Table 1. To measure and
visualize the expression of TTSS genes in living P. aeruginosa, the promoter of the exsCBA operon
(8) isolated from the CHA strain was fused with
gfpmut3 (encoding green fluorescent protein [GFP])
(1) in the P. aeruginosa-Escherichia coli
vector pUCP20 (25). First, the gfpmut3 gene was
cloned into XbaI-PstI-digested pUCP20.
P. aeruginosa strains transformed with
pUCP20-gfpmut3 showed high GFP fluorescence due to the
activity of plac present just upstream from the cloned
gfpmut3 gene. To avoid interference with plac activity, the
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.538-542.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Expression of ExsA in trans Confers Type III
Secretion System-Dependent Cytotoxicity on Noncytotoxic
Pseudomonas aeruginosa Cystic Fibrosis
Isolates
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
10 region of plac was deleted with mutagenic
oligonucleotide 5'GCTCACAATTCCACACACGAGCCGGAAG using the
Altered Sites in vitro mutagenesis system (Promega, Madison, Wis.)
according to the manufacturer's instructions. The sequence of
mutagenized plasmid (named pIA101*) was confirmed by sequencing. No
background GFP fluorescence could be detected in P. aeruginosa strains transformed with pIA101* when cultivated in
Luria-Bertani (LB) medium. The pexsC (8) region
was amplified by PCR using genomic DNA of CHA as the template. Primers 5'TCGGATCCCCCATGAAGGACGTC and
5'AGGGATCCTGCGAACTCGGCAAGCAG were synthesized,
with BamHI sites (underlined) incorporated at the 5' ends to
facilitate cloning. A 280-bp pexsC PCR product was cloned
into the BamHI site of pIA101*, giving pIApC, and introduced by electroporation into the CHA strain (6). To test
transcriptional fusion, gfp expression under control of
pexsC was measured in the CHA(pIApC) strain grown either in
LB or in LB supplemented with 5 mM EGTA and 20 mM MgCl2, a
condition known to activate pexsC transcription
(26). GFP expression in individual bacteria was visualized
by fluorescence microscopy (Zeiss) and quantified with a FluoroImager
(Vistra Fluorescens). The expression of pexsC-gfp in
CHA(pIApC) increased about eightfold during growth under activating conditions (Fig. 1). When the fusion was
introduced into the exsA-mutated CHA strain CHA-D1
(2), no expression of GFP could be detected under
activating growth conditions (Fig. 1). These results showed that the
pexsC-gfp fusion could be used as an efficient reporter for
monitoring transcription of the exsCBA operon.
TABLE 1.
Bacterial strains and plasmids used in this study

View larger version (23K):
[in a new window]
FIG. 1.
GFP fluorescence in P. aeruginosa isolates
transformed with reporter plasmid pIApC, grown in LB medium (stippled
bars) or in LB medium supplemented with 5 mM EGTA and 20 mM
MgCl2 (inducing conditions) (solid bars). Error bars
represent the standard deviation. Data are from at least three
independent experiments.
To determine the transcriptional level of the exsCBA operon in noncytotoxic P. aeruginosa isolates, the pexsC-gfp fusion was introduced into strains by electroporation (6). The transformants were selected on Pseudomonas Isolation Agar (Difco) supplemented with 1,000 µg of carbenicillin per ml. For measurement of pexsC activity, the transformed strains were cultivated overnight at 37°C and 300 rpm in LB liquid medium with 300 µg of carbenicillin per ml. Each culture was diluted to an optical density at 600 nm (OD600) of 0.1 and grown to an OD600 of 1 under two culture conditions: in LB medium, where pexsC was not active (no GFP fluorescence could be detected), and in calcium-depleted LB medium, a condition that activated pexsC. GFP fluorescence was quantified in a 96-well plate with a FluoroImager using 2.5 × 108 bacteria per well, washed once with sterile water, and resuspended in 100 µl of sterile water.
In four selected cytotoxic strains, CF6, CF11, CF12, and REN0,
harboring the pexsC-gfp fusion, the expression of
pexsC was increased six- to ninefold under inducing
conditions, similar to the activation observed for CHA(pIApC) (Fig. 1).
In contrast, strains that were found to be noncytotoxic toward PMNs and
macrophages over a period of 6 h in the infection model showed no
transcriptional activation of pexsC under conditions of
calcium depletion (Fig. 1). These results indicate that the absence of
secretion of TTSS proteins in vitro and, as a consequence, the absence
of a cytotoxic phenotype in the infection model may be due to
inefficient transcriptional activation of the exsCBA
operon (3). The third gene of the operon
encodes ExsA, the transcriptional activator necessary for the
expression of operons encoding type III secretion complex proteins, translocation proteins, and effectors (26, 28). In order to see whether the absence of functional ExsA is responsible for the noncytotoxic phenotype, we introduced the functional
exsA gene, isolated from CHA, into all 12 noncytotoxic
strains. The plasmid pDD2, which was previously used to complement the
CHA exsA mutant strain, CHA-D1, contains the exsA
gene under the control of a constitutive promoter. The ability of the
transformants to secrete in vitro TTSS proteins was first tested.
Bacteria were grown in calcium-depleted LB medium, and extracellular
proteins were analyzed by 0.1% sodium dodecyl sulfate-12%
polyacrylamide gel electrophoresis. The protein profiles were compared
to the protein profile obtained with the CHA strain, in which secreted ExoS, ExoT, PopB, and PopD were previously identified by
matrix-assisted laser desorption ionization-time-of-flight mass
spectrometry (2). The results showed that 11 out of the 12 strains harboring pDD2 were able to secrete TTSS proteins (ExoS, ExoT,
PopB, and PopD) in vitro (Fig. 2 and data
not shown). To check that the in vitro reactivation of the type III
secretion was due to the expression of exsA in trans, the
same strains were electrotransformed with pDD3, in which
exsA is cloned in the antisense orientation with respect to
the promoter. As expected, the strains harboring pDD3 were unable to
secrete type III proteins under inducing conditions (data not shown).
|
Only one isolate, CF3(pDD2), although efficiently transformed, was unable to secrete any of the TTSS proteins in vitro. We considered the possibility that the constitutive promoter isolated from CHA and used to control exsA expression in pDD2 might not be recognized in the CF3 strain. To test this, plasmid pIAX12 containing gfpmut3 placed under the control of the same constitutive promoter as in pDD2 was introduced into the isolates CF3, CF5, and CHA. The fluorescences (in arbitrary units) of CF3(pIAX12), CHA(pIAX12), and CF5(pIAX12) were 26,361 ± 687, 31,722 ± 1588, and 21,620 ± 812, respectively. These similar levels, compared to the low level of fluorescence with transformed strains with pIA101* as a negative control (data not shown), indicated that the promoter is equally active in the three strains. Thus, the nonreactivation of secretion in CF3(pDD2) is not due to a dysfunction of the promoter but may be to a mutation acting further downstream in the activation process.
P. aeruginosa CF isolates which are cytotoxic to PMNs and
macrophages ex vivo demonstrate in vitro secretion of TTSS proteins (3). In order to test whether the reactivation of in vitro secretion of TTSS proteins in the strains transformed with pDD2 was
sufficient to reactivate cytotoxicity, infection experiments using PMNs
and J774 macrophages were performed as previously described (2,
3). Briefly, PMNs were isolated from whole blood by Percoll
gradient centrifugation, and the macrophage cell line J774 was grown in
Dulbecco modified Eagle medium (Gibco) supplemented with 10%
heat-inactivated fetal calf serum (Gibco). For infection, bacteria were
grown to an OD600 of between 1 and 1.2 after dilution of
overnight cultures at an OD600 of 0.1, washed once and
resuspended in the appropriate medium. Infection was carried out in
96-well plates with a multiplicity of infection of 10 in a
CO2 incubator at 37°C. Cytotoxicity was determined by
measuring the release of the cytosolic enzyme lactate dehydrogenase
into infection supernatant using a Cytotoxicity Detection Kit (Roche
Molecular Biochemical, Meylan, France). The cytotoxic CF isolate CHA
was able to induce type III secretion-dependent cell death of PMNs
(Fig. 3) and macrophages (data not
shown), with 80% cell lysis measured at 3 h postinfection. The
same phenotype was previously described for cytotoxic CF clinical isolates (2, 3). Untransformed noncytotoxic isolates,
similarly to the exsA mutant CHA-D1, were unable to provoke
cell lysis, even after 6 h postinfection (Fig. 3). The isolates
CF5, CF9, CF10, CF15, CF17, RIE, K569, REN3, and REN4 transformed with
pDD2 were able to induce 30 to 55% PMN death (Fig. 3) and 30 to 90% macrophage death (data not shown) at 3 h postinfection. The
strains harboring pDD3 (exsA cloned in the inverse
orientation) were still noncytotoxic, with values similar to those
obtained with untransformed strains (data not shown). The variations of
cytotoxicity observed between strains in ex vivo infection model (Fig.
3) were not related to the quantity of secreted type III proteins in
vitro (Fig. 2). We have previously shown that, although cytotoxic,
different CF isolates may have different kinetics of cytotoxicity
(3). This might be due to differences between strains in
cell growth, adhesion, level of activation of the TTSS, and/or
resistance to PMNs. Two pDD2-transformed strains (CF2 and CF4) which
were capable of secreting TTSS proteins in vitro failed to induce cell
death of PMNs and macrophages (Fig. 3 and data not shown). Although the
secretion complex seemed to be intact, an inefficient translocation
process may have caused the lack of cytotoxicity.
|
In this study, we have shown that 9 out of 12 successfully transformed strains previously characterized as noncytotoxic in a cellular model of infection could be made cytotoxic just by expressing the exsA gene in trans from a constitutive promoter. ExsA is an activator of TTSS operons, and its expression is autoregulated (26). ExsA is encoded by the last gene in the exsCBA operon, which is expressed from the regulated pexsC promoter. The exsC and exsB genes are involved in the processing effect on exsA mRNA (10). The cytotoxic phenotype conferred by exsA in trans using a constitutive promoter suggests that the ExsA protein, which is necessary for the expression of the TTSS, is not functional in noncytotoxic strains. This might result either from a mutation(s) in the exsCBA operon affecting the coding or regulatory regions or from inappropriate signaling in the regulatory cascade upstream from pexsC.
The bacterial TTSS is an efficient mechanism for eukaryotic cell intoxication and in many cases a requirement for pathogen survival in the host. However, the synthesis of the system is an energetically expensive process for the bacterial cell, involving more than 20 proteins that make up the secretion complex, translocation complex, effectors, and regulatory proteins. As is the case for the complex regulatory network controlling the synthesis of the P. aeruginosa exopolysaccharide alginate (16), the regulation of the TTSS might involve a signaling pathway upstream from ExsA, which would allow expression of TTSS genes only when appropriate conditions inside the host are met. The environmental stimuli and the signaling pathway upstream from pexsC affecting expression of the regulatory loci remain to be determined. Our survey of CF clinical isolates showed that about 96% of noncytotoxic strains possess genes capable of encoding proteins of the TTSS (3). Our results suggest that these strains are all potentially cytotoxic.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grant 98033 from the Association Française de Lutte contre la Mucoviscidose (AFLM) and by grants from DGA (DSP/STTC).
We thank F. Morel (Laboratoire d'Enzymologie, CHU-Grenoble) for whole blood and A. Colbeau and W. Dischert for valuable discussion and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: DBMS/BBSI, CEA Grenoble, 17 rue des Martyrs, 38054 Grenoble cedex 09, France. Phone: 33.4.76.88.34.83. Fax: 33.4.76.88.51.85. E-mail: btoussaint{at}cea.fr.
Editor: E. I. Tuomanen
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Cormack, B. P., R. H. Valdivia, and S. Falkow. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173:33-38[CrossRef][Medline]. |
| 2. |
Dacheux, D.,
I. Attree,
C. Schneider, and B. Toussaint.
1999.
Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system.
Infect. Immun.
67:6164-6167 |
| 3. |
Dacheux, D.,
B. Toussaint,
M. Richard,
G. Brochier,
J. Croize, and I. Attree.
2000.
Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils.
Infect. Immun.
68:2916-2924 |
| 4. | Döring, G. 1993. Pseudomonas aeruginosa as an opportunistic pathogen. Plenum Press, New York, N.Y. |
| 5. | Elborn, J. S., and D. J. Shale. 1990. Cystic fibrosis. 2. Lung injury in cystic fibrosis. Thorax 45:970-973[Medline]. |
| 6. | Enderle, P. J., and M. A. Farwell. 1998. Electroporation of freshly plated Escherichia coli and Pseudomonas aeruginosa cells. Biotechniques 25:954-956[Medline], 958. (Erratum, 26:716, 1999.) |
| 7. | Finck-Barbancon, V., J. Goranson, L. Zhu, T. Sawa, J. P. Wiener-Kronish, S. M. Fleiszig, C. Wu, L. Mende-Mueller, and D. W. Frank. 1997. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol. Microbiol. 25:547-557[CrossRef][Medline]. |
| 8. |
Frank, D. W., and B. H. Iglewski.
1991.
Cloning and sequence analysis of a trans-regulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa.
J. Bacteriol.
173:6460-6468 |
| 9. | Frithz-Lindsten, E., Y. Du, R. Rosqvist, and A. Forsberg. 1997. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol. Microbiol. 25:1125-1139[CrossRef][Medline]. |
| 10. |
Goranson, J.,
A. K. Hovey, and D. W. Frank.
1997.
Functional analysis of ExsC and ExsB in regulation of exoenzyme S production by Pseudomonas aeruginosa.
J. Bacteriol.
179:1646-1654 |
| 11. |
Govan, J. R., and V. Deretic.
1996.
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol. Rev.
60:539-574 |
| 12. | Hauser, A. R., P. J. Kang, and J. N. Engel. 1998. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol. Microbiol. 27:807-818[CrossRef][Medline]. |
| 13. |
Hovey, A. K., and D. W. Frank.
1995.
Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon.
J. Bacteriol.
177:4427-4436 |
| 14. |
Hueck, C. J.
1998.
Type III protein secretion systems in bacterial pathogens of animals and plants.
Microbiol. Mol. Biol. Rev.
62:379-433 |
| 15. | Lee, C. A. 1997. Type III secretion systems: machines to deliver bacterial proteins into eukaryotic cells? Trends Microbiol. 5:148-156[CrossRef][Medline]. |
| 16. |
Martin, D. W.,
M. J. Schurr,
M. H. Mudd,
J. R. Govan,
B. W. Holloway, and V. Deretic.
1993.
Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients.
Proc. Natl. Acad. Sci. USA
90:8377-8381 |
| 17. | McElvaney, N. G., H. Nakamura, P. Birrer, C. A. Hebert, W. L. Wong, M. Alphonso, J. B. Baker, M. A. Catalano, and R. G. Crystal. 1992. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest. 90:1296-1301. |
| 18. |
McGuffie, E. M.,
D. W. Frank,
T. S. Vincent, and J. C. Olson.
1998.
Modification of Ras in eukaryotic cells by Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
66:2607-2613 |
| 19. | Nakamura, H., K. Yoshimura, N. G. McElvaney, and R. G. Crystal. 1992. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest. 89:1478-1484. |
| 20. |
Olson, J. C.,
J. E. Fraylick,
E. M. McGuffie,
K. M. Dolan,
T. L. Yahr,
D. W. Frank, and T. S. Vincent.
1999.
Interruption of multiple cellular processes in HT-29 epithelial cells by Pseudomonas aeruginosa exoenzyme S.
Infect. Immun.
67:2847-2854 |
| 21. | Olson, J. C., E. M. McGuffie, and D. W. Frank. 1997. Effects of differential expression of the 49-kilodalton exoenzyme S by Pseudomonas aeruginosa on cultured eukaryotic cells. Infect. Immun. 65:248-256[Abstract]. |
| 22. | Pederson, K. J., A. J. Vallis, K. Aktories, D. W. Frank, and J. T. Barbieri. 1999. The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins. Mol. Microbiol. 32:393-401[CrossRef][Medline]. |
| 23. | Sawa, T., T. L. Yahr, M. Ohara, K. Kurahashi, M. A. Gropper, J. P. Wiener-Kronish, and D. W. Frank. 1999. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat. Med. 5:392-398[CrossRef][Medline]. |
| 24. | Toussaint, B., I. Delic-Attree, and P. M. Vignais. 1993. Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD promoter. Biochem. Biophys. Res. Commun. 196:416-421[CrossRef][Medline]. |
| 25. | West, S. E., H. P. Schweizer, C. Dall, A. K. Sample, and L. J. Runyen-Janecky. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86[CrossRef][Medline]. |
| 26. |
Yahr, T. L., and D. W. Frank.
1994.
Transcriptional organization of the trans-regulatory locus which controls exoenzyme S synthesis in Pseudomonas aeruginosa.
J. Bacteriol.
176:3832-3838 |
| 27. | Yahr, T. L., J. Goranson, and D. W. Frank. 1996. Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway. Mol. Microbiol. 22:991-1003[CrossRef][Medline]. |
| 28. |
Yahr, T. L.,
A. K. Hovey,
S. M. Kulich, and D. W. Frank.
1995.
Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene.
J. Bacteriol.
177:1169-1178 |
| 29. |
Yahr, T. L.,
A. J. Vallis,
M. K. Hancock,
J. T. Barbieri, and D. W. Frank.
1998.
ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system.
Proc. Natl. Acad. Sci. USA
95:13899-13904 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|